Cdk2/Cyclin Inhibitory Peptide I (Tat-LFG) acetate, a CDK2 inhibitor, kills U2OS osteosarcoma cells in a dose-dependent manner [1].
In Vitro, Cdk2/Cyclin Inhibitory Peptide I (0-150 μM; 24 h) acetate kills U2OS osteosarcoma cells in a dose-dependent manner[1].
References:
[1]. Chen YN, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9.
In Vitro, Cdk2/Cyclin Inhibitory Peptide I (0-150 μM; 24 h) acetate kills U2OS osteosarcoma cells in a dose-dependent manner[1].
References:
[1]. Chen YN, et al. Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4325-9.